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Abstract
As part of the peer review process for the European Journal of Cardio-Thoracic Surgery (EJCTS) and the Interactive CardioVascular and
Thoracic Surgery (ICVTS), a statistician reviews any manuscript that includes a statistical analysis. To facilitate authors considering submitting
a manuscript and to make it clearer about the expectations of the statistical reviewers, we present up-to-date guidelines for authors on
statistical and data reporting speciﬁcally in these journals. The number of statistical methods used in the cardiothoracic literature is vast, as
are the ways in which data are presented. Therefore, we narrow the scope of these guidelines to cover the most common applications sub-
mitted to the EJCTS and ICVTS, focusing in particular on those that the statistical reviewers most frequently comment on.
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INTRODUCTION
The European Journal of Cardio-Thoracic Surgery (EJCTS) and the
Interactive CardioVascular and Thoracic Surgery (ICVTS) receive
more than 3000 papers per year, many of which feature data and
statistical analyses. The level of reporting varies from the simple
presentation of data in tabular format, to the development of a
clinical risk prediction model. Regardless of whether the manu-
script was co-authored by a biostatistician or not, the majority of
these papers are reviewed by a statistical consultant experienced
in cardiothoracic and cardiovascular surgical data. This is part of
the peer-review process that every research article undergoes in
these journals [1].
Up until now the EJCTS and ICVTS have asked authors to follow
guidelines for data reporting and nomenclature published in 1988
[2] and also the International Committee of Medical Journal
Editors (ICMJE) Uniform Requirements for Manuscripts (http://
www.icmje.org/icmje-recommendations.pdf; 29 January 2015,
date last accessed). While these are excellent guidelines that
authors should continue to use, we want to build on these for the
speciﬁc EJCTS and ICVTS readership, with a view towards improv-
ing the quality of research published.
Here, we present new guidelines for authors on statistical and
data reporting. These are built on our experience of reviewing
manuscripts and from the guidelines of other biomedical journals
[3], and as such represent only one view of what is considered im-
portant. It is emphasized that these are only guidelines and not
strict rules. In quite a few places the guidelines are more ‘what not
to do’ than ‘what to do’, which is in response to common errors.
Moreover, this is not a guide on how to perform statistical analyses
or choose appropriate methodology—for that one should consult
an experienced statistician (preferably at the study design stage)—
but rather on the presentation and minimum reporting required.
There are a number of comprehensive textbooks on the topic of
medical statistics that readers might consider for studies that
require standard analyses [4, 5]. In places, however, we do direct
readers to appropriate references where it is considered beneﬁcial
to authors, especially in circumstances where standard required
methodology is frequently overlooked or underreported (e.g.
model ﬁt diagnostics).
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The number of statistical methods used in the cardiothoracic
literature is vast, as are the ways in which data are presented.
Therefore, we narrow the scope of these guidelines to cover the
most common applications submitted to the EJCTS and ICVTS,
focusing in particular on those that the statistical reviewers most
frequently comment on. This is evident from our bias towards
commenting on Kaplan–Meier curves. In fact, by virtue of the
scope and readership of the EJCTS and ICVTS, these guidelines are
extremely narrow indeed.
Adoption of these guidelines should, in principle, lead to a
clearer manuscript, thus allowing the reviewers to focus on what
really matters—the science.
INTRODUCTION SECTION
Title
Titles should make clear the study design. Ostentatious or ‘catchy’
titles for manuscripts are to be avoided in reports with substantial
analytical content. For example, ‘A propensity-score matched
analysis of 376 patients comparing surgery to no medical treatment
for very mild aortic stenosis’ is more informative than ‘Much ado
about nothing: Should we operate on patients with aortic stenosis?’.
Aims and objectives
• Clearly state the objectives of the study. In particular, where
appropriate, state any primary hypotheses that are to be tested.
• The authors should state clearly if the study hypotheses were
prespeciﬁed or not.
MATERIALS ANDMETHODS SECTION
Study design
• Most studies conform to a standard design; for example, a rando-
mized controlled trial or meta-analysis. Guidelines for standardiz-
ing, strengthening and increasing the transparency in the reporting
of biomedical research in these areas are freely available and have
been published. All authors should utilize these statements, which
generally come with downloadable and printable checklists. If uti-
lized, authors should declare which statement(s) they adhered to.
Guidelines relevant to authors publishing in the EJCTS and ICVTS
are available from:
W CONSORT [‘Consolidated standards of reporting trials’] state-
ment: http://www.consort-statement.org.
W MOOSE [‘Meta-analysis of observational studies in epidemi-
ology’] statement: reference [6].
W PRISMA [‘Preferred reporting items for systematic reviews and
meta-analyses’] statement: http://prisma-statement.org/.
W STARD [‘Standards for the reporting of diagnostic accuracy
studies’] statement: http://www.stard-statement.org/.
W STROBE [‘Strengthening the reporting of observational studies in
epidemiology’] statement: http://www.strobe-statement.org/.
W TRIPOD [‘Transparent reporting of a multivariable prediction
model for individual prognosis or diagnosis’] statement: http://
www.tripod-statement.org/.
W SQUIRE [‘Standards for quality improvement reporting excel-
lence’] statement: http://www.squire-statement.org/.
W TREND [‘Transparent reporting of evaluations with nonrando-
mized designs’] statement: http://www.cdc.gov/trendstatement/.
W CHEERS [‘Consolidated health economic evaluation reporting
standards’] statement: reference [7].
W SPIRIT [‘Standard protocol items: recommendations for inter-
ventional trials’] statement: http://www.spirit-statement.org/.
For other study designs not listed here, authors should consult the
Equator Network (http://www.equator-network.org/library/) for
specialist reporting guidelines where available.
• The source of the subjects should be detailed including, where ap-
propriate, details of inclusion and exclusion criteria, and over
what time period the data were collected.
• A rationale for sample sizes should be provided. Merely stating
what software was used is insufﬁcient. The statistical method
used for estimation of effect sizes or assessment of statistical
signiﬁcance should be evaluated, including in the latter case
whether a one- or two-sided test was used; if pilot data were
available and used; what was the expected or clinically meaning-
ful effect size sought; and what statistical precision of estimation,
or power if signiﬁcance testing is being used, was required. The
statistical reviewer should be able to validate the calculation
from the details provided.
• Authors should recognize that small sample sizes could preclude
certain statistical methods. For example, ﬁtting a multivariable lo-
gistic regression model to 25 subjects with 9 outcome events and
10 predictors is not sensible. Sample sizes and statistical methods
should always be considered during the study design phase.
• Any study involving the randomization of subjects to different
treatment arms should state the technique used, including
whether simple, block, stratiﬁed or covariate-adaptive methods
were employed [8]. Details on the randomization process such as
blinding [9] and who was responsible for the randomization and
allocation should also be noted [10, 11].
Outcomes
• The study outcomes should be clearly stated and deﬁned.
Frequently reported outcomes include:
W Operative mortality: it should be stated whether this is (i) all-
cause or procedure-speciﬁc mortality; (ii) the associated time
point, for example in-hospital mortality; 30-day mortality;
90-day mortality; 30-day mortality including patients who died
after 30 days but without discharge; within-intensive care unit
mortality etc. The terms ‘early mortality’ or ‘operative mortality’
should not be used without the inclusion of a deﬁnition in the
‘Materials and Methods’ section. We emphasize that operative
mortality is a binary outcome, and as such the appropriate stat-
istical analyses are restricted to such data.
W Late mortality: it should be stated whether this is (i) all-cause or
procedure-speciﬁc mortality; (ii) what the time origin is (gener-
ally this will be the time of surgery or randomization). We em-
phasize that late mortality is generally accepted as being
recorded as a time-to-event outcome, and as such the appro-
priate statistical analyses are restricted to such data, namely
survival analysis.
W Postoperative complications: each complication should be clearly
deﬁned. If a composite outcome is used, for example ‘major’
and ‘minor’ complications, then the individual components of
each should be stated. Generally, postoperative complications
are taken to be binary or count data in a ﬁxed time window
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(e.g. postoperative stay), but might also be evaluated as a time-
to-event outcome.
W Time to reintervention: it should be stated (i) what interventions
are included (for example, if measuring the time to reinterven-
tion following surgical aortic valve replacement, would a trans-
cathether aortic valve replacement be counted, or are surgical
procedures counted only?); (ii) the time origin, which will typ-
ically be the time of surgery unless, for example, a landmark
analysis is used [12].
W Continuous measurements: it should be stated when and how the
measurements were taken. For example, interleukin-6 might
have been measured by taking a blood sample 1 h before
bypass and 1 h after removal of the cross clamp.
W Count data: data capturing an integer number of events (which
might be binary). For example, the number of nodes resected.
Care should be taken to distinguish whether the authors are
counting subjects or counting a variable within a subject, as
this will dictate the appropriate statistical methodology.
W Ordinal data: for example, mitral valve regurgitation grade fol-
lowing valve repair or replacement surgery. The scale, deﬁni-
tions and time of measurement should be presented.
W Longitudinal data: measurements taken repeatedly over time for
each patient, either at ﬁxed and regular time intervals or at dif-
ferent time points for each patient. For example, measuring the
aortic gradient in outpatient clinics. Times of data collection
should be clear and presented in a suitable format (tabular if
regular periods, subject-speciﬁc time-series otherwise).
• Details should be provided on the collection of outcome data.
For example, late mortality data might be collected using (a com-
bination of ) direct contact with patients, data linkage to a nation-
al or regional death register, contact with primary physicians,
telephone or postal questionnaire surveys. Outcomes might be
collected actively in the case of, say, a cohort study or by inter-
view in, say, the case of a case–control study.
• For valve-related outcomes including structural valve deterioration
and thromboembolic events, authors should consult reference [13].
• For transcatheter aortic valve implantation (TAVI)-related out-
comes, authors should consult reference [14].
• Composite outcomes can increase statistical efﬁciency, particularly
in studies where individual outcome components have a low inci-
dence [15]. They also attract strong criticism [16]. Composite end-
points should be deﬁned during the study design, and not after, to
avoid any perception of manipulation. Additionally, complete
data on individual component outcomes should be reported
separately to facilitate interpretation.
• Consistency in outcome terminology is important. When reporting
late events, there are often differing opinions on whether these
should be referred to as ‘late’ or ‘mid-term’ events. This is subjective
and application dependent; however, we stress that consistency in
terminology is required to avoid confusion. Similarly, authors might
report the terms ‘operative mortality’ and ‘in-hospital mortality’.
It is not always clear whether these are the same or different
outcomes; hence one (appropriately deﬁned) term should be
used consistently throughout.
Study variables
• Details on the data acquisition methods should be provided. For
example in case-series analyses one might interrogate a hospital
unit computer records system, or manually enter data from
obtained patient records. In a laboratory based study, details of
the experiment should be provided with speciﬁc reference to
the data measurement process.
• Deﬁnitions of study variables, such as patient characteristics and
perioperative data should be provided where appropriate. For
example, it is not clear whether ‘recent myocardial infarction’
means within 30 or 90 days, or whether ‘smoker’ includes only
currently active smokers or those who recently quit.
• When referring to the European System for Cardiac Operative Risk
Evaluation (EuroSCORE), authors should explicitly state whether
they are referring to the additive EuroSCORE, logistic EuroSCORE
or EuroSCORE II [17–19]. Furthermore, one should avoid the
term ‘log EuroSCORE’, as ‘log’ universally means ‘logarithm’, not
‘logistic’. In this case, use ‘logistic EuroSCORE’ throughout.
Registration of clinical trials
• In accordance with the Clinical Trial Registration Statement from
the ICMJE (http://www.icmje.org/about-icmje/faqs/clinical-trials-
registration/) all clinical trials published in the EJCTS and ICVTS
must be registered in a public trials registry at or before the onset
of participant enrolment. For any clinical trials commencing prior
to 1 January 2008, retrospective registration will be accepted. For
details, see the ICMJE website or reference [20].
STATISTICAL METHODS SECTION
It is advisable that a statistician be consulted to ensure that statis-
tical methods are adequately described and applied and results
are correctly interpreted. This is especially important in cases
where non-standard methodology was applied.
Core requirements
• All statistical methods used should be identiﬁed. It is not acceptable
to merely report that a particular software package was used to
analyse the data.
• Potential selection bias in non-randomized studies where group
comparisons are to be made should be elucidated.
• Comparisons in non-randomized studies, in particular observational
studies, are difﬁcult to make. Statistical methods should be used to
adjust as much as possible for possible selection bias. Methods
include multivariable modelling, matched pairs analysis and pro-
pensity score methodology. It is important to note that these tech-
niques do not guarantee adequate correction for selection bias,
but are generally more reliable than no adjustment at all.
• In randomized trials it is unnecessary to test for baseline differences
between treatment groups unless there are concerns regarding
the randomization process. In a randomized trial we know that
baseline differences are by chance and therefore testing does
not add value [21]. Instead, the authors should evaluate differ-
ences with regard to their ability to introduce bias in the analysis.
Multivariable analysis models adjusting for such factors are ap-
propriate tools for such an investigation.
• Routinely used statistical methods, for example Student’s t-test and
Fisher’s exact test, do not require extensive details. However, in
cases where misinterpretation is possible, authors should seek to
provide additional details; for example stating an independent
samples t-test was used rather than a paired-samples t-test. It
should also be made clear where each method was used and for
what purpose.
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• Avoid reporting that ‘tests were used as appropriate’. It is not always
clear what is meant by this, let alone what is appropriate.
Clariﬁcation on what tests were used should always be explicit.
Especially, do not offer two separate tests for the same hypothesis
without a clear description of which test is used in which situation.
• Advanced methods that are not regularly published in the EJCTS
and ICVTS require explanation. Authors should consider includ-
ing appropriate biostatistical references and/or an online meth-
odological appendix. When a more advanced method has been
used instead of a valid, more familiar approach, an explanation
should be provided.
• Statistical methods, especially advanced methods, rely on statistical
assumptions. For example, a particular statistical hypothesis test may
rely on distributional assumptions such as normality, which if vio-
lated might require a preprocessing data transformation or applica-
tion of a non-parametric test. Comparisons between groups might
rely on the assumption of equal variances. Other commonly
overlooked assumptions are described in these guidelines at
the relevant sections.
• Statistical software used should be referenced (either as an
in-line reference or citation) including the version number.
Recommended references for the most commonly used soft-
ware are:
W SPSS: http://www-01.ibm.com/support/docview.wss?uid=swg21
476197
W SAS: http://www.sas.com/en_us/legal/editorial-guidelines.html
W R: http://cran.r-project.org/doc/FAQ/R-FAQ.html#Citing-R
W GraphPad Prism: http://www.graphpad.com/guides/prism/6/
user-guide/index.htm?citing_graphpad_prism.htm
W Stata: http://www.stata.com/support/faqs/resources/citing-
software-documentation-faqs/
W JMP: http://www.jmp.com/support/notes/35/282.html
Any advanced ‘add on’ packages should also be referenced as
appropriate, with version numbers where available.
• Outlier data should not automatically be eliminated from an ana-
lysis unless there are additional reasons to cast doubt on the
credibility of the data. The inﬂuence of outliers on inferences
should, however, be examined and consideration given to robust
statistical methods.
• Some tests and methods, e.g. t-tests, depend theoretically on the
distributional assumption of normality. However, in many cases
these methods are quite robust to slight violations of this assump-
tion. Use of a pretest for normality (e.g. the Kolmogorov–Smirnov
test) as an automated tool to choose between a parametric
(e.g. t-test) or non-parametric (e.g. Mann–Whitney U-test) test for
comparison can be misleading. This is because, with small sample
sizes, many tests of normality have low power for rejecting the as-
sumption of normality, leading to false conﬁdence. On the other
hand, normality tests can reject the null hypothesis under very
slight departures from normality when sample sizes are large.
• When reporting that a correlation will be calculated, note that
there are multiple measures, and the reader should be explicitly
told which is reported. Standard choices include Pearson’s
sample correlation r and Spearman’s rank correlation.
• Phrasing and terminology should be used correctly.
W The term ‘multivariable’ is preferred over ‘multivariate’ when re-
ferring to regression modelling with a single outcome variable
and multiple explanatory variables. ‘Multivariate’ should be
reserved for modelling more than one outcome variable [22].
Similarly, the term ‘univariable’ is preferred over ‘univariate’.
The term ‘bivariate’ should only be used in the special case of
two outcomes (a special case of multivariate analysis).
W The term ‘non-parametric’ should refer to a statistical method,
not data themselves. For example, the statement that ‘the
Mann–Whitney U-test was used when data were non-
parametric’ is incorrect. The Mann–Whitney U-test is a non-
parametric test.
W The terms ‘incidence’ and ‘prevalence’ are routinely confused.
Incidence is deﬁned as the number of new cases of a characteristic
in a population over some ﬁxed time; e.g. number of new rheum-
atic fever cases over a year for a single hospital. Prevalence is
deﬁned as the proportion of a population that has the characteris-
tic; e.g. the proportion of patients undergoing mitral valve repair
(the ‘population’) with diabetes mellitus (the ‘characteristic’).
W The term ‘correlation’ is often reserved in statistics for analyses
reporting correlation coefﬁcients. Authors should attempt to
avoid using it in cases where the terms ‘association’ or ‘relation-
ship’ might be more appropriate, for example when comment-
ing on an odds ratio.
W When calculating survival using the Kaplan–Meier estimator,
the phrase ‘actuarial survival’ should not be used; simply write
‘survival’ [23]. If life-table methods are used, then ‘actuarial sur-
vival’ is an appropriate term.
W The term ‘signiﬁcance’ should not be used colloquially, and
should be reserved only for reference to statistical signiﬁcance
or clinical signiﬁcance (sometimes referred to as clinical rele-
vance or clinical importance), being explicit about which.
W Quantiles (e.g. terciles, quartiles, quintiles, deciles, percentiles
etc.) deﬁne the cut-points, not the groups. For example, if divid-
ing BMI data into ﬁve groups using the quintiles, the groups
would not be called quintiles, they would be called ﬁfths [24].
• Deﬁne all statistical acronyms and notation at ﬁrst use, including
standard deviation (SD), standard error (SE), standard errors of
the mean (SEM), conﬁdence interval (CI), r, R, rho, beta.
Non-independent data
• Paired data arise in situations such as a patient having a meas-
urement recorded twice, such as before and after intervention
(e.g. patient-reported pain score); or from a matched case–
control study. It is important to use an appropriate test that
accounts for the paired nature of the data, and to clearly note
this in the manuscript. For example, one might consider using a
Wilcoxon signed-rank test or paired t-test in the case of continu-
ous variables.
• Repeated measures data typically arise in serially recorded data at
different time points. For example, interleukin-10 measurements
from subjects might be recorded on postoperative days 1, 3, 5
and 7 for a series of patients who underwent bypass surgery
either off-pump or on-pump. Ignoring the dependency, or cor-
relation, between responses within individual subjects can
reduce power and precision in some cases. Standard tests for
analysing repeated measures data include repeated measures
ANOVA and Friedman’s test. In the case of the former, authors
should describe clearly (i) the underlying model and whether
any interactions with time were analysed; (ii) how any assump-
tions, e.g. sphericity, were evaluated. For further information, in-
cluding how to present the results of a repeated measures
ANOVA, consult reference [25]. More ﬂexible statistical method-
ology that can also be used falls under the umbrella of longitu-
dinal data analysis [26].
• When describing analysis methods, it should be clear what the
unit of analysis is. For example, in thoracic research it is common
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for measurements to be taken on several lymph nodes from the
same patient. If the unit of interest is the patient, then the mea-
surements might be considered clustered within the patient.
That is, measurements taken from different lymph nodes in the
same patient would likely be more similar than those taken from
different patients. This is another type of repeated data. It is im-
portant to use methods appropriate for this clustering. For
example use of random-effects models [27] or generalized esti-
mating equations [26].
• Studies that measure a continuous variable at some baseline fol-
lowed by a measure at some point afterwards, e.g. following
surgery or 1-year following treatment, might calculate percentage
change scores of the type: 100 × (f – b)/b, where f is the follow-up
measure and b is the baseline measure. These percentage
change scores are then often statistically compared between
groups, e.g. open-surgery repair vs endovascular repair. In many
situations, however, this is not generally recommended [28].
Analysis of covariance (ANCOVA) is the preferred approach for
comparison, owing to its superior statistical power [29].
Hypothesis tests and multiple comparisons
• It should be explicitly stated which hypotheses were prespeciﬁed
and which were data-driven. Limiting testing to those hypoth-
eses that were identiﬁed a priori is preferred. Post hoc analyses
have their own value, but the interpretation of such analyses is
different and more challenging.
• In analyses where post hoc analysis is to be performed, the
authors should make clear that generally such analyses are of
only hypothesis-generating value. The authors could apply suit-
able statistical techniques that account for multiple testing.
However, while this could account for some of the multiplicity, it
is still unlikely to remove the exploratory nature of such analyses.
For groups with a natural ordering (e.g. different dosages of an
anticoagulant), data should be analysed using methods that test
for trend [30].
• Merely stating that ‘multiple comparisons were accounted for’ or
‘results have been adjusted for multiplicity’ is insufﬁcient information.
The authors should name the method used to adjust for multiplicity.
• The Mann–Whitney U-test (or Wilcoxon-Mann–Whitney test) for
comparing two continuous or ordinal variables is not a test for
comparing the difference in medians except in a particular special
case [31]. Therefore, authors should avoid making this claim.
• Authors routinely report that categorical data were compared
using either Pearson’s χ2 test or Fisher’s exact test, as appropriate.
The statement ‘as appropriate’ should be spelled out precisely.
Often it is an implicit reference to whether or not the expected
cell frequencies are <5. There is now evidence to suggest that
this rule of thumb is outdated. Current recommendations are to
use Pearson’s χ2 test with an (N − 1)/N correction factor (where
N is the total sample size being included in the test) applied to
the test statistic in situations where the expected cell frequencies
are >1 [32]. Some statistical software packages allow (or even
automate) the Yates’ continuity correction factor. Such correc-
tions should be reported if used.
Missing data
• Don’t ignore the issue! Many studies will encounter missing data
to some degree, which without ﬁrst handling generally precludes
statistical analysis, e.g. regression. It is also one of the main limita-
tions to standard analyses, for example longitudinal analysis.
A description of methods used should be given.
• Missing data needs to be carefully described and discussed, as they
may limit the conclusions that can be made. At least in the pres-
ence of a considerable amount of missing data, several different
methods or sensitivity analyses should be applied for the analysis
in order to see if conclusions are robust against missing data.
• Not including important variables in analyses due to missing data
is not appropriate.
• Imputation of data by the mean or median of observed values
(in the case of continuous or ordinal variables with missing data),
or by the mode of observed values (in the case of categorical
variables) results in overconﬁdence (P-values are too small; CIs
are shrunk). This is because it treats the imputed data as if they
were actually observed measurements.
• Case-complete and missing-indicator methods are generally infer-
ior to the multiple imputation method [33, 34].
• Multiple imputation is generally a better method than simple
imputation rules. Using multiple imputation methodology requires
authors to propagate the uncertainty through into the calcula-
tion of effect size SEs. Many statistical software packages now
incorporate analytical routines that can automate this process
[35–37]. However, multiple imputation methods, like all methods,
have limitations.
Regression analyses (general overview)
The following provides information on how regression analyses
should be speciﬁed and performed. This is speciﬁcally important
when the objective of the study is linked to a regression analysis
like a prognostic factor analysis or a prediction model. Otherwise,
the amount of information provided could be more limited. For
more sophisticated models the underlying methodology could be
considerably more complex, and should therefore be understood
when such models are applied and the results interpreted. In such
cases it is strongly advisable to consult a statistician ﬁrst.
• Terminology used in the context of regression analysis varies. In
general, one is interested in modelling the relationship between
an outcome variable (also often referred to as the dependent
variable or response variable) and one or more explanatory vari-
ables (also often referred to as independent variables, predictors
or covariates).
• In many studies, especially observational studies, the outcome of
interest will be associated with many other variables (e.g. patient
demographics and comorbidities) in addition to the primary
variables of interest (e.g. treatment). These covariates should be
included in the regression models where sample sizes permit. All
variables included in a model, including any higher-order terms,
should be listed.
• Model development strategies should be clearly described in such
a way that an independent analyst could validate the reported
results independently if they had access to the original data. In
particular:
W Was prescreening of variables for inclusion decided on the
basis of univariable hypothesis tests or on clinical reasoning?
W Was a stepwise regression model algorithm used? Or were all a
priori identiﬁed variables included?
W Were any variables ‘forced’ into the model, even where a
model development algorithm was used?
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• If univariable testing is used as a prescreening method for variable
inclusion in a multivariable model, then in general a threshold of
P < 0.05 is too strict and will introduce selection bias. Typically a
higher threshold should be used, for example P < 0.25.
• Stepwise regression is a broad term that captures forward, back-
ward and bidirectional regression algorithms [38]. It should be
stated which approach was used and what the inclusion and/or
exclusion criteria were for the algorithms, as these vary by statis-
tical software packages. Merely stating what software was used is
not sufﬁcient.
• Stepwise regression has a number of major limitations, despite its
appeal, that authors should be aware of before using such
methods [39], especially in the context of small datasets [40]. For
example (examples taken from reference [41]):
W The selection is typically unstable, sensitive to small perturba-
tions in the data. Addition or deletion of a small number of
observations can change our chosen model markedly.
W SEs of regression coefﬁcients are negatively biased, CIs are too
narrow, P-values are too small and R2 or analogous measures
are inﬂated.
W Regression coefﬁcients are positively biased in absolute value.
W It has severe problems in the presence of collinearity.
• Continuous explanatory variables often do not need to be categor-
ized. Categorizing a continuous predictor into intervals (including
two intervals, known as dichotomization) can lead to a number of
statistical inferential problems including bias and loss of power
[42]. Sometimes there might be a reason to categorize a variable
based on either statistical evidence or for clinical reasons. In such
a situation, this should be reported, and suitable efforts for deﬁn-
ing a good cut-point for dichotomization should be applied.
However, in general predetermined cut-points are preferred.
• The functional form of explanatory variables should be correctly
speciﬁed. For example, in a logistic regression model relating
in-hospital mortality to body mass index (BMI), linearity is unlikely
to hold between the log-odds of mortality and BMI because
patients with either extremely low BMI (very underweight) or
extremely high BMI (morbidly obese) will be expected to have a
higher risk of mortality. One might model the hypothesized
U-shape in this particular example by including a quadratic term.
Assessing functional form varies by regression model; however,
standard methods include:
W Plotting explanatory variables against residuals for ordinary
linear regression [43].
W Plotting smoothed Martingale residuals (with and without the
explanatory variable in the model) against the explanatory
variable for Cox proportional hazards regression [44].
W Use of splines [39] or fractional polynomial transformations [45].
W Replacing the continuous variable by a percentile-categorized
variable, and plotting midpoints against ﬁtted model coefﬁ-
cients. Note that the categorical variable method is a crude
assessment, and should not automatically be used in place of
continuously modelled variables [46].
• Multicollinearity is an issue that can affect any regression model. In
general, it can lead to an inﬂation in type II errors (increased SEs for
estimated coefﬁcients), which makes identiﬁcation of predictors dif-
ﬁcult, as well as misleading coefﬁcients. There are numerous techni-
ques available for the identiﬁcation of multicollinearity (e.g.
variance inﬂation factors), which should be considered [47].
• Interaction terms allow for two variables to have non-additive
effects in a regression model. For example, a treatment effect
might be different in smokers and non-smokers. Use of interaction
terms is similar to ﬁtting regression models to different subsets of
the data (e.g. in smokers and non-smokers). Interaction terms—
just as the case for subgroup analyses—should be speciﬁed in
advance; post hoc searching can lead to spurious signiﬁcant
effects. It should be noted that models including interaction terms
are generally more difﬁcult to interpret, thus requiring authors to
carefully present and interpret their results [48, 49].
• If the study objective is to test a speciﬁc hypothesis, then an
a priori sample size calculation should made in most circum-
stances. Formulae for sample size calculations are readily avail-
able for standard regression models including linear and logistic
regression [50] and Cox proportional hazards regression [51].
Linear regression
• Ordinary linear regression depends on a number of assumptions
that should be assessed, which include (in addition to the others
mentioned above):
W Linearity: see the comment on ‘functional form’ above.
W Homogeneity: also referred to as homoscedasticity; the vari-
ance of the errors should be independent of the explanatory
variables.
W Independence of errors: errors should be independent of one
another. This is particularly important if samples contained
repeated measurements on subjects, or if there is an obvious
clustering (e.g. different hospitals).
W Normality: if one is interested in making inferences about
the model, particularly with small sample sizes, then it is often
assumed that the errors should be normally distributed.
W Diagnostics tools for the evaluation of these assumptions gener-
ally involve inspection of the residuals [43].
• If diagnostic analyses suggest that a revision to the model is
required, e.g. a transformation to the outcome variable to stabil-
ize the variance, then descriptions of the methods should be
made available and results provided.
• The coefﬁcient of determination (R2) should be reported, stating
whether it is the standard or adjusted value.
Logistic regression
• It is not always sufﬁcient to consider the sample size (i.e. number of
subjects) alone when considering a study design that will involve
a multivariable logistic regression model. The number of events
per variable (EPV) ratio is also important. Although the rule of
thumb has been the requirement of 10 EPV, this is not a strict
necessity and in general is application dependent [52, 53].
• There are a number of goodness-of-ﬁt tests and model diagnostics
for evaluating a logistic regression model ﬁt [46, 54]. A brief de-
scription of what methods were used should be provided (with
the results presented in the ‘Results’ section).
Cox proportional hazards regression and survival
analysis
• The proportional hazards assumption is fundamental to the Cox
model, and any (gross) violation of it can potentially result in mis-
leading inferences [55]. All Cox proportional hazard regression
models are therefore required to include details and results of
how this assumption was evaluated. Standard approaches include:
W smoothed scaled Schoenfeld residual plots [56];
W complementary log–log Kaplan–Meier plots [57];
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W the Grambsch–Therneau test [56];
W including time-dependent coefﬁcients into the regression
model [58].
• Where required, models should be adjusted to compensate for any
violation of the proportional hazards assumption. Standard
approaches include the stratiﬁed Cox proportional hazards re-
gression model and time-dependent variables/coefﬁcients, or
use of a different model [59].
• Similarly to logistic regression, the sample size should be consid-
ered in relation to the total number of events (i.e. the number of
subjects that reached the endpoint), not just the total number of
subjects or the total follow-up time [13].
• The Cox proportional hazards regression model is ubiquitous in
the biomedical literature. However, authors should consider the
availability of other time-to-event regression models depending
on their speciﬁc study, as theoretical arguments might imply
more suitable models. For example, modelling the time to struc-
tural valve deterioration of implanted bio-prostheses can exploit
the theoretical knowledge that the hazard will increase with
time. Parametric survival models such as Weibull regression or
other accelerated failure time models can be used, and offer po-
tentially greater power [57].
• Do not include ﬁxed predictors in the model that are only observed
after the time origin. For example, if modelling the time to death
and the time origin is the commencement of surgery, then do
not include postoperative complications (e.g. stroke) or post-
baseline measurements as a (static) predictor. It is not possible to
‘reach’ forward in time! A classic example involves heart trans-
plantation. In the Stanford Heart Transplant Study, patients who
were eligible for a transplant were followed until death or cen-
sorship [60]. The objective of the study was to assess whether
patients who received a transplant live longer than those not re-
ceiving a transplant. Comparing the survival distributions
between those who received a transplant at some point and
those who did not is, however, not appropriate. Patients who
received a transplant must have lived until the point of trans-
plantation, and so must have contributed survival time in the
non-transplant group [61]. In short, transplantation status is not
known at the time of eligibility; therefore, we should not condi-
tion on this variable it in advance. In such situations one might
consider:
W including a time-dependent covariate [58];
W using a landmark analysis [12];
W not including measurements that occurred after the time origin.
However, this would be application dependent, and would be
guided by the study objectives.
• If multiple measurements are recorded for one or more predictors,
then including all data using time-varying covariates can lead to
more informative inferences. For example, in a follow-up study
of patients undergoing aortic valve replacement, patients might
return to clinic regularly to have valve gradient measurements
taken. These gradient measures can be included in a model as a
time-dependent covariate. Time-varying covariates can also be
used in cross-over trials to model change in treatment [61].
• For modelling time to non-terminal events, for example time
to reintervention, patients who die might be considered a
competing risk. Similarly, when modelling the time to a cause-
speciﬁc mortality, other causes of death can be considered as
competing risks. Ignoring competing risks can lead to biased
estimates. Standard methodology for overcoming this issue
include summarizing the survival data using the cumulative
incidence function [62].
• The area under the receiver operating characteristic curve is some-
times reported in the context of survival analysis. Ignoring the
time-to-event nature (including the censoring) of the data and
treating it as a purely binary outcome should be avoided. There
are extensions of discriminatory ability measures that can be
used, e.g. Harrell’s C-statistic [63], and generalizations, e.g. time-
dependent ROC curves [64].
• It is often of interest to compare the survival of a sample of sub-
jects to a demographically matched population, typically obtained
from national actuarial tables. The standard log-rank test is not
appropriate for this comparison; however, there are a number of
proposed one-sample survival tests [65].
• The log-rank test does not compare survival at ﬁxed time points;
it compares the distribution of survival times between two
(or more) groups. Statements such as ‘the survival at 5 years was
65% in Group A and 75% in Group B (P = 0.012)’ are therefore
unclear and misleading when the P-value is calculated from the
log-rank test. Tests that calculate the difference in survival at
ﬁxed time points are available [57]; however, time points should
be limited and deﬁned at the study design stage.
Risk model development and validation
• There are a number of statistical challenges when developing a
risk prediction model, which have been extensively described in
the literature. Authors who are unfamiliar with the issues are
encouraged to consult a guide on model development prior to
any analysis [63, 66].
• All developed risk prediction models should be validated, which
can be internal or external. Validation by arbitrary data splitting
(e.g. 60%/40% training/validation split) should be avoided in
preference to bootstrap resampling methods [39, 67, 68]. At the
most intuitive level, splitting data are wasteful, especially when
sample sizes are small to moderate.
• If an additive risk score is developed, it should be explicit on how
the scores were derived from the statistical model [69].
• The external validation of risk prediction models should describe
both the model calibration and discrimination [70, 71].
• When assessing the model calibration, there is a growing need to
reconsider the suitability of the Hosmer–Lemeshow test, espe-
cially with large sample sizes [72–74]. Instead, consider comple-
menting it with a range of other calibration tests and diagnostics,
in particular with the support of calibration plots with overlaid
smoothed calibration curves [70, 75]. For testing whether the cali-
bration curve is ‘ideal’ consider either a recalibration regression
test [67, 76] or Spiegelhalter’s Z-test [77].
• External validation of a risk prediction model requires a substantial
effective sample size. This should be incorporated into the design
stage of validation studies [78].
• Assessing a risk prediction model ‘off label’ should be explicitly stated,
and conclusions should not mislead readers that the performance
was for the intended outcome. For example, the EuroSCORE II was
developed to predict in-hospital mortality. ‘Validating’ the model in
a sample of patients with the outcome of 30-day mortality would
be ‘off label’, and so caution should be taken.
Propensity scores and matching
• The use of statistical hypothesis tests for evaluating balance before
and after matching is widely criticized [79]. The simplest accepted
approach is to calculate the standardized bias [also known as the
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standardized difference (in means)] for each variable:
d ¼ 100 ðx1  x2Þ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðs21 þ s22Þ=2
q
where xi and s2i denote the sample mean and variance of the data
for group i = 1, 2. There are a number of other approaches that
can be considered also [80, 81].
• Variations of the standardized bias for other propensity score
methods including regression adjustment [82] and inverse prob-
ability treatment weights are available [83].
• Evidence of imbalance (|d| > 10%; signiﬁcant P-values) in baseline
variables between propensity score-matched groups should not
be overlooked [84]. Propensity score model development is
an iterative process. Authors should consider including polyno-
mial terms; interactions; or including additional confounding
variables [85].
• At the time of writing, no dedicated statement on the reporting
of propensity score-matching methods are known to the EJCTS.
However, the systematic reviews by Austin contain a useful
number of recommendations on the minimum reporting require-
ments [79]. These include describing:
W the propensity score model development, including the prior
selection of variables for inclusion in the model;
W the matching algorithm used, along with details of any tuning
attributes (e.g. caliper widths). This should also report whether
1:Mmatching was employed and whether matching was with or
without replacement;
W methods used for assessing balance;
W statistical methods for estimation of treatment effects.
• There is debate about whether treatment effects should be esti-
mated using methods for matched data or unmatched data.
Austin vociferously argues that the correct statistical methods for
estimation of treatment effects are those that account for the
matching [79]. However, this has been rebutted by other experts
[86, 87]. Frustratingly, there is no obvious right or wrong answer
to this. Notwithstanding this lack of consensus, authors should
nonetheless avoid interchanging the application of statistical
methodology appropriate for matched and unmatched data
when comparing different outcomes.
• Goodness-of-ﬁt tests (e.g. the Hosmer–Lemeshow test) and the
C-statistic are not generally informative about the adequacy of
the propensity score model speciﬁcation [81].
• Propensity score methodology is predominantly focused on the
case of two treatment arms. There is a growing body of research
into performing propensity score matching for three or more
groups; however, they are foundationally and technically more
challenging [88, 89]. An exceptionally well-detailed description
of methods involving such sophisticated methodology would be
required for review.
• Including the propensity score in a multivariable regression model
with a treatment indicator variable is a common technique for es-
timation of treatment effects [90]. However, it does not preclude
one from ensuring that regression model assumptions are satis-
ﬁed. This includes ensuring that the outcome model is adequately
speciﬁed in the same way one would any other multivariable
model. If any violation of assumptions are detected, then quadrat-
ic terms, logit transformations or regression splines might be used
to model the score correctly [84].
• When applying propensity score matching, the unmatched sub-
jects (which can be in both treatment arms) should ideally also
be proﬁled [91].
• Matching can be done outside of the propensity score paradigm,
for example in matched case–control studies. The process by
which matching was performed should be described, including:
(i) whether 1-to-1 matching (or otherwise) was performed;
(ii) what variables were used to match on, and if exact matching
was used (e.g. how was matching handled for continuous vari-
ables?); (iii) in the cases of >1 match, what rules were applied?
• When subjects are matched exactly on a set of variables, then stat-
istical tests that are appropriate to matched data are most efﬁ-
cient [92].
• Propensity score-matching methodology might be precluded in
the cases of very small numbers of subjects in the treatment group.
Diagnostic studies
• Report the known diagnostic sensitivity and speciﬁcity of any test
used with reference to the information source.
• Sensitivity, speciﬁcity, positive predictive value (PPV) and negative
predictive value (NPV) are all measures of the diagnostic ability of
a test. The PPV and NPV are not intrinsic to the test—it depends
also on the prevalence [93, 94].
• Using speciﬁcity to compare two tests can mask important differ-
ences. For example, speciﬁcities of 94 and 97% look high;
however, the false-positive rates are 6 and 3%, respectively—the
former is twice as large as the latter. Reporting the 2 × 2 classiﬁ-
cation table is advisable.
Receiver operating characteristic curves
• When comparing the area under two (or more) ROC curves calcu-
lated from the same data, it is necessary to account for correl-
ation [95, 96].
• Calculating cut-points from ROC curve analysis requires reporting
what method was used. There are numerous methods, with
Youden’s J-statistic and the point closest to the top-left part, i.e. (0, 1),
of the ROC curve plot being two frequently used approaches [97].
• The AUC can be insensitive to detection of model improvement.
Two widely accepted measures that overcome this issue are the
net reclassiﬁcation improvement (NRI) and integrated discrimin-
ation improvement (IRI) [98].
DATA REPORTING
• Summary statistics should be reported on subjects (e.g. age,
gender, procedures performed and comorbidities), making use
of tables where possible.
• Repetition of summary data should be avoided by not presenting
the same data in multiple formats. For example, data reported in
a table can be referred to in the main text without duplication of
summary statistics.
• If different interventions are being considered, then characteristics
should be summarized within each different arm along with an
appropriate statistical comparison.
• Averages should always be presented with an appropriatemeasure
of variability (e.g. SD or the 25th to 75th percentile interval).
• The term ‘average’ should be avoided when used in reference to
actual numerical values. Instead, report the actual statistic being
reported or compared. For example, when stating ‘the average was
55%’, it is not clear whether this is a mean, median or otherwise,
which might have implications should the distribution be skewed.
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• If not implicit, then authors should explicitly state what summary
statistics are being reported. For example, reporting that ‘age in a
sample was 65 years (43, 78)’ is unhelpful as it is not clear (i)
whether the average age was a mean, median or otherwise; (ii)
whether the interval denotes the minimum and maximum, the
ﬁrst and third quartile, or otherwise. Extra care is especially
required for studies reporting SDs and SEs.
• When reporting summary statistics, it should be clear how these
were calculated if missing data were present. For example,
whether they are case-complete statistics, or maybe calculated
following an imputation.
Continuous data
• Continuous variables (e.g. age, BMI) can be presented as mean and
SD, or if there is evidence of the distribution of data being skewed
(can be gauged using a histogram for example), then a useful
summary is the median with the 25th to 75th percentile interval
(equivalent to the 1st to 3rd quartile interval). In most situations,
length-of-stay data will be positively skewed. Note that technically
the interquartile range (IQR) is deﬁned as the 3rd quartile minus
the 1st quartile (i.e. a single number); however, the interval is the
preferred statistic for reporting as it conveys more information.
• Descriptive statistics should not be reported as inferential statistics.
For example, the mean patient age should be reported with a
SD, not a SE or CI.
• While the minimum and maximum values are informative, they
are easily inﬂuenced by outlier values and should therefore not
be used in place of the 25th to 75th percentile interval when de-
scribing non-normal distributions, but rather in addition to it.
• When reporting associations between two continuous variables
(e.g. Pearson’s sample correlation; simple linear regression), a
scatterplot of data should be presented, possibly including a
ﬁtted regression line/curve. A correlation coefﬁcient alone can
mask complex relationships (see Fig. 1).
• When deﬁning thresholds, ensure that all values are captured. For
example, if deﬁning two groups as <50% ejection fraction and
>50% ejection fraction, one of them needs to include an equality
so that an ejection fraction of exactly 50% is captured, e.g. ≤50%.
Categorical data
• Categorical and binary variables should be reported as counts
and percentages. Reporting counts without percentages makes
comparison between groups, e.g. different treatment arms, with
unequal group sizes (denominators) difﬁcult.
• The denominator for percentages should always be made clear if
not implicit. For example, if reporting 70% of 200 patients had
valve replacement surgery, and 50% had a mechanical valve
prosthesis, then it should be clear whether this is 50% of all
patients (i.e. denominator = 200) or 50% of patients undergoing
valve surgery (denominator = 140).
• Ordinal variables such as New York Heart Association dyspnoea
grade should be reported as counts and percentages, not as
mean and SD.
• Avoid mixing percentages and proportions when reporting data.
Additionally, avoid using the terms interchangeably to prevent
misinterpretation.
• Always check that numbers add up correctly. This is one of the
most frequently encountered errors found in tables within
manuscripts submitted. For example, if there are 50 patients, and
it is reported that 30 had a mitral valve repair, and 18 had a
mitral valve replacement, then what procedures did the other 2
patients have?
• Always check that percentages have been calculated correctly.
Rounding errors are a common error. For example, 1/11 = 9.1%,
not 9.0% when rounded to 1 decimal place.
Presentation and notation
• Use of the ‘±’ symbol for reporting SD and SE values is confusing
unless explicitly stated [100]. Therefore, it is recommended that
authors do not use it and instead use parenthesis with a statement
on what precision measurement is being used; for example,
replace 5.6 ± 0.5 with 5.6 (SD: 0.5) or 5.6 (SE: 0.5) as appropriate.
• Use of the dash symbol for reporting intervals (including CIs,
minimum and maximum ranges, and percentile intervals) can be
confusing, especially in the presence of negative data values.
Therefore, it is recommended authors use commas or the word
‘to’; for example replace (95% CI: −3.4 –−1.5) with (95% CI: −3.4,
−1.5) or (95% CI: −3.4 to −1.5).
• EJCTS convention is to use points for decimal marks, not commas.
This applies to all numerical reporting in the text, tables and
ﬁgures.
• The rounding of summary statistics for patient data such as means
and SDs should be guided by the precision of the underlying data.
Generally, for example, age, BMI and left ventricular ejection frac-
tion, do not need to be reported to more than 1 decimal place.
Biomarker data, for example, might be recorded to a higher preci-
sion, and any rounding of summary statistics should reﬂect this.
Percentages can generally be reported to 0 or 1 decimal place
without misrepresentation. When the denominator is <100, per-
centages should always be rounded to 0 decimal places (i.e. as an
integer).
• Units of measurement should be reported throughout the manu-
script. For example, serum creatinine might be measured in
milligrams per deciliter or micromoles per litre.
• Avoid using the tilde symbol () as shorthand for the word
‘approximately’.
Figures and tables
• In general, when reporting many items of data, tables and ﬁgures
are the preferred presentation format rather than text. Figures
are in particular preferred for very large amounts of data. When
there are very few data, e.g. 3 or 4 mean values, then ﬁgures are
a waste of space, unless additional information is to be overlaid
(e.g. the raw values).
• Provide footnotes for tables and ﬁgures to deﬁne any abbrevia-
tions, acronyms or symbols used.
• Flowcharts—a minimum requirement for randomized controlled
trials and meta-analyses—are a useful construct for observational
data studies with inclusion and exclusion criteria, and those with
subgroup analyses.
• Bar charts are preferred over pie charts for reporting data on pro-
portions with multiple groups.
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RESULTS SECTION
• Selective reporting (or ﬁltering of results) is to be avoided. If a
study was designed to test a ﬁxed number of hypotheses, then
all test results should be reported regardless of statistical signiﬁ-
cance.
• Deviations from study design should be reported. This includes
‘going off-piste’ and performing additional hypothesis tests
(for example, subgroup analyses, which are likely to include far
fewer subjects; or combining endpoints such as different post-
operative complications in a single composite indicator) on the
basis of primary ﬁndings.
• Appropriate effect sizes should be reported. A P-value is not an
effect size. Standard effect sizes for studies in the EJCTS and
ICVTS include:
W Odds ratios (ORs) for binary data and logistic regression (with a
logit-link function).
W Relative risks (or risk ratios) for binary data and logistic regres-
sion (with a log-link function).
W Hazard ratios (HRs) for Cox proportional hazards regression.
W Regression coefﬁcients for risk prediction models or multiple
linear regression.
W Differences in means for continuous measurements and
proportions.
W Differences in survival at a ﬁxed time point.
• A careful distinction should be made between reporting relative
and absolute effect sizes. For example, reporting a HR vs differ-
ence in median survival, or an OR vs difference in proportions.
• It is desirable to report the size of the difference in a clinically mean-
ingful way in addition to P-values instead of just the latter for
primary hypothesis tests. For example, one might report incidence
differences of ‘16 vs 40%; P = 0.008’ rather than just ‘P = 0.008’.
• Explicitly state what the effect size is, as opposed to writing an
acronym. For example, state ‘odds ratio (OR)’ at ﬁrst instance in
the Abstract and the main text rather than just ‘OR’. It is useful to
note that two frequently observed errors are authors: (i) inter-
changing ‘OR’ and ‘HR’ (i.e. OR and HRs); and (ii) confusing both
‘OR’ and ‘HR’ with ‘RR’ (relative risk).
• Regression models should, in most circumstances, be reported in
full. That is, all coefﬁcients (or corresponding effect sizes) should
be summarized.
• If appropriate, regression model intercepts should be reported.
For example, these are required if the regression model is used
as a risk prediction model or to estimate a lung topology
outcome from spirometry data.
• CIs are preferred over P-values. For example, reporting that a par-
ticular treatment was statistically signiﬁcantly associated with an
increase in length of hospital stay is less informative than report-
ing that the mean increase in length of hospital stay was 1.3 days
(95% CI: 0.2–2.4).
• CIs convey the precision of an estimate. Awide CI, whether statis-
tically signiﬁcant or not, should be interpreted with caution.
Figure 1: Scatterplots of four different datasets known as Anscombe’s quartet [99]. Each dataset consists of 11 data points (orange points) and have nearly identical
statistical properties, including means, sample variances, Pearson’s sample correlation (denoted as r in the ﬁgure), and linear regression line (blue lines). This well-
known quartet highlights the importance of graphing data prior to analysis, and why statistical reviewers often ask for such graphs to be made available.
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• For most studies it is sufﬁcient to report P-values to 3 decimal
places if <0.10, and 2 decimal places if ≥0.10. If a P-value is
<0.001, then reporting ‘P < 0.001’ is sufﬁcient unless there are an
unusually large number of hypothesis tests (e.g. genetic differen-
tial expression data). Avoid reporting unnecessarily high degrees
of precision or only reporting P-values to 1 decimal place.
• When reporting P-values, avoid the following:
W Arbitrary bounds, for example P < 0.05; P > 0.4 or ‘P less than 0.05’.
W Reporting ‘n.s.’ or ‘NS’ (i.e. ‘non-signiﬁcant’) merely because it is
greater than some arbitrary value.
W P = 0.000 when rounded.
Instead report the exact P-value as described earlier.
• The most appropriate precision of effect sizes will vary by study.
ORs and HRs can often be reported adequately to 1–2 decimal
places; however, clinical risk prediction models might want to
consider reporting coefﬁcients to a greater precision.
• When a study involves following patients over time, the follow-up
data should be succinctly summarized. This might include the
median (and range) follow-up time and/or total person-years.
Additionally, the date of the last follow-up check and whether
patients were lost during the follow-up (and why) should be
reported. Note that if a median follow-up time is provided, the
authors should specify how they calculated this. Just taking the
median time to event or censoring in a group is often not sufﬁcient
as this is biased by treatment group differences. It is preferable to
use an inverse Kaplan–Meier by having censoring time as an event
and censor patients with an event at the time of the event.
Figures (general)
• Figures should be provided in a high-resolution format (see EJCTS
and ICVTS ‘Instruction to Authors’: http://www.oxfordjournals.
org/our_journals/ejcts/for_authors/manuscript_instructions.html)
to enable clarity in presentation. Consideration should be given
to the font size, point size and line widths.
• Authors should consider making use of colour ﬁgures where ap-
propriate. Note that the printing of colour ﬁgures is free of
charge in the EJCTS and ICVTS. However, please note the Editor
may use his discretion when deciding which ﬁgures to publish in
colour.
• All axes of ﬁgures should be clearly labelled, including specifying
any units of measurement.
• If P-values or other statistical results are reported in a ﬁgure, a
description of the hypothesis and methodology should be pro-
vided in the ﬁgure legend.
• If asterisks (or other symbols) are used in a plot, for example to
indicate a particular signiﬁcance threshold, they should be
deﬁned in the legend, and preferably consistent throughout the
manuscript.
• Error bars are sometimes shown in plots. If ‘error bars’ are to be
added, it must be clearly stated in the ﬁgure legend what they
denote, e.g. ±1 SD, ±1 SE, 95% CI or otherwise.
• If ﬁgures are presented on transformed scales (e.g. log paper) or
axes begin from an arbitrary origin (e.g. having a Kaplan–Meier
survival curve only shown on 50–100% cumulative survival), then
this should be drawn to the reader’s attention in the ﬁgure
legend.
• ‘Dynamite plots’ (bar charts with error bar lines) should be
avoided [101]. They hide important data and are not always suit-
able. Dot plots and box-and-whiskers plots are useful alterna-
tives when sample sizes are small and large, respectively.
• Three-dimensional bar charts and pie charts and other ‘special
effects’ charts, all of which are ubiquitous to desktop ofﬁce soft-
ware suites, should not be used in any circumstance, as they are
difﬁcult to read and contrast.
Figures (Kaplan–Meier curves; Fig. 2)
• When there is potential for ambiguity, it is preferred that the
horizontal axis label of a Kaplan–Meier graph should read ‘Time
from … (units)’, where the ‘…’ denotes the time origin (e.g. ran-
domization, time of surgery, discharge) and ‘units’ denotes the
units of the axis (e.g. months, years).
• The horizontal axis should be naturally discretized according to
the length of follow-up. For example, it would be most appropri-
ate to use units of years rather than blocks of 100 days in a
Kaplan–Meier curve extending out to 5 years.
• Displaying ‘error bars’ at ﬁxed time points on Kaplan–Meier curves
is not particularly useful, especially when there are multiple
groups (strata) as they overlap and add unnecessary distraction. If
a measure of precision is required, CI bands should be included.
• Kaplan–Meier graphs should be displayed with a table showing
the number of patients at risk at a sequence of regularly spaced
time points. The table should be aligned with the horizontal axis
(Fig. 2).
• Censoring information should be provided using tick marks
(or similar). These should also be stated in the graph, for example
using a legend or noted in the ﬁgure description. In some situa-
tions, e.g. analysis of large national registries, tick marks might be
omitted.
• There is a greater uncertainty about the survival towards the end of
the Kaplan–Meier curve. To avoid misinterpretation about this
region of the graph, the horizontal [time] axis might be truncated
when there remain only a few patients at risk.
DISCUSSION SECTION
• The discussion and conclusions should be transparent if a ﬁnding
was based on pre-speciﬁed analysis or an exploratory post hoc
ﬁnding. In the case of the latter, it should generally be viewed as
exploratory and of a hypothesis-generating nature requiring con-
ﬁrmation by a further study.
• A statistically signiﬁcant effect demonstrates an association, but
does not constitute evidence of causation. In general, causation is
difﬁcult to infer, except perhaps in randomized controlled trials.
• Effects found to be statistically signiﬁcant should be evaluated for
clinical signiﬁcance. For example, a study that ﬁnds surgery
reduces the mean time patients spend in intensive care by 0.1
days might be statistically signiﬁcant, but might not have clinical
signiﬁcance.
• P-values only provide evidence against a hypothesis, never evi-
dence in favour of it. In other words absence of evidence is
never evidence of absence. For example, a P-value of 0.60 only
tells us that there is insufﬁcient evidence for an effect, which
might be due to either no effect being present, or insufﬁcient in-
formation in the data sample due to a small sample size, large
variability or both [103].
• A P-value does not equal the probability that a null hypothesis is
true. Therefore, P-values cannot be used to rank evidence. For
example, if a Hosmer–Lemeshow test was applied to evaluate
two separate risk prediction models, then the size of the
P-values does not confer which is the ‘better’ model.
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• Study weaknesses should be well thought out. Authors should go
beyond merely commenting on the study sample size and
whether it was observational data or not. Consideration should be
given towards the potential for study inclusion/exclusion criteria to
distort the results; methodology applied; any assumptions made
(e.g. missing data); the sample size in contrast to the number of
events; any unmeasured confounders, especially those that might
be strong; violation of statistical assumptions etc. The implications
of study weaknesses on the ﬁndings should be determined.
• An attempt should be made to explain unexpected results or
those that contradict existing ﬁndings with reference to the data
and analysis design.
• Conclusions should only be based on ﬁndings in the study that
can be backed up by study data and analyses. General statements
beyond study ﬁndings should not be made.
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